Catheter Precision (VTAK) Liabilities and Shareholders Equity (2017 - 2026)

Catheter Precision (VTAK) has 10 years of Liabilities and Shareholders Equity data on file, last reported at $35.1 million in Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 41.47% year-over-year to $35.1 million in Q1 2026; TTM through Mar 2026 was $76.5 million, a 45.57% increase from a year earlier, with the FY2025 full-year figure at $15.9 million, down 42.89% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $35.1 million, up from $15.9 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for VTAK reached as high as $48.5 million in Q1 2023 and fell as low as $109000.0 in Q2 2025.
• Historically, Liabilities and Shareholders Equity has averaged $25.9 million across 5 years, with a median of $26.6 million in 2024.
• Across the five-year window, Liabilities and Shareholders Equity soared 104.27% in 2023 and tumbled 42.89% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $16.8 million in 2022, then soared by 82.56% to $30.7 million in 2023, then decreased by 9.65% to $27.8 million in 2024, then slumped by 42.89% to $15.9 million in 2025, then jumped by 121.22% to $35.1 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $35.1 million in Q1 2026, $15.9 million in Q4 2025, and $25.5 million in Q3 2025.